The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.
第一作者:
Paul,Rolan
第一单位:
Clinical Pharmacology Consulting and University of Adelaide Medical School, Adelaide, Australia.
作者:
医学主题词
人类(Humans);别构调节(Allosteric Regulation);抗焦虑药(Anti-Anxiety Agents);动物(Animals);临床试验, Ⅰ期(主题)(Clinical Trials, Phase I as Topic);精神障碍(Mental Disorders);男(雄)性(Male);成年人(Adult)
DOI
10.1002/cpdd.1609
PMID
41014090
发布时间
2026-01-30
- 浏览0
Clinical pharmacology in drug development
2026年15卷2期
e1609页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



